Short Interest in CDT Equity Inc. (NASDAQ:CDT) Increases By 326.9%

CDT Equity Inc. (NASDAQ:CDT) saw a large growth in short interest in the month of June. As of June 30th, there was short interest totaling 167,688 shares, a growth of 326.9% from the June 15th total of 39,284 shares. Currently, 3.9% of the shares of the stock are short sold. Based on an average daily trading volume, of 36,828,063 shares, the short-interest ratio is presently 0.0 days.

Wall Street Analyst Weigh In

CDT has been the topic of a number of recent analyst reports. Weiss Ratings reissued a “sell (e+)” rating on shares of CDT Equity in a report on Wednesday, June 24th. Wall Street Zen lowered CDT Equity to a “strong sell” rating in a research note on Saturday, June 27th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, CDT Equity presently has an average rating of “Sell”.

CDT Equity Stock Performance

Shares of CDT Equity stock traded down $0.03 on Friday, hitting $0.38. 211,716 shares of the company traded hands, compared to its average volume of 18,995,698. The stock has a market capitalization of $1.85 million, a P/E ratio of -0.00 and a beta of 1.49. CDT Equity has a 52 week low of $0.38 and a 52 week high of $492.00. The business has a 50-day simple moving average of $1.06 and a 200 day simple moving average of $13.60.

CDT Equity (NASDAQ:CDT) last released its earnings results on Wednesday, April 15th. The company reported $695.11 EPS for the quarter.

About CDT Equity

Conduit Pharmaceuticals Inc, a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility.